Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 3, 2008, Pages 266-273

  Manolakopoulos, S ^a,e   Bethanis, S ^a   Koutsounas, S ^a   Goulis, J ^b   Vlachogiannakos, J ^c   Christias, E ^d   Saveriadis, A ^c   Pavlidis, C ^a   Triantos, C ^a   Christidou, A ^a   Papatheodoridis, G ^d   Karamanolis, D ^c   Tzourmakliotis, D ^a  

^a IASO GENERAL HOSPITAL   (Greece)

^b Aristotle University of Thessaloniki   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e Athens University Medical School ^*  (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FIBROSIS; LIVER FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; VIRUS HEPATITIS; VIRUS RESISTANCE;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; STATISTICS, NONPARAMETRIC;

EID: 37549047969     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03567.x     Document Type: Article

References (25)

1. Lok AS, McMahon B. Chronic hepatitis B. Hepatology 2007 45 : 507 39.
2. Funk ML, Rosemberg DM, Lok AS. World-wide epidemiology of HBeg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002 9 : 52 61.
3. Ballard AL, Boxall EH. Epidemiology of precore mutants of hepatitis B in the United Kingdom. J Med Virol 2000 62 : 463 70.
4. Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995 1 : 7 36.
5. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001 34 : 617 24.
6. Papatheodoridis GV, Hadziyannis SJ. Current management of chronic hepatitis B. Aliment Pharmacol Ther 2004 19 : 25 37.
7. Gish RG, Perrillo RP, Jacobson IM. Customizing the management of chronic hepatitis B virus infection. Semin Liver Dis 2007 27 (Suppl. 1 9 17.
8. Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2004 99 : 57 63.
9. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of patients with HBeAg-negative chronic hepatitis B under nucleos(t)ide analogues maintenance therapy starting with lamivudine. Hepatology 2005 42 : 121 9.
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006 131 : 1743 51.
11. Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005 43 : 937 43.
12. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003 38 : 1419 27.
13. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004 126 : 81 90.
14. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004 126 : 91 101.
15. Kessler HH, Pierer K, Dragon E, et al. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B. Clin Diagn Virol 1998 9 : 37 43.
16. Manolakopoulos S, Bethanis S, Elefsiniotis J, et al. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome. Aliment Pharmacol Ther 2006 23 : 787 95.
17. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696 9.
18. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002 36 : 219 26.
19. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching to adefovir therapy in lamivudine resistant HBeAg-negative chronic hepatitis B. Hepatology 2007 45 : 307 13.
20. Lampertico P, Marzano A, Levrero M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology 2006 44 : 693A 4A.
21. Lee YS, Suh D, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006 43 : 1385 91.
22. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2006 42 : 1414 9.
23. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003 125 : 292 7.
24. Villeneue JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003 39 : 1085 9.
25. Locarnini S, Qi W, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil therapy for patients with chronic hepatitis B (abstract). J Hepatol 2005 42 : 17.